• Fisheries and Aquatic Sciences
• /
• v.9 no.2
• /
• pp.64-69
• /
• 2006

Cytochrome P450 (CYP1A) gene expression in the liver and sex steroid levels in plasma were investigated in olive flounder (Paralichthys olivaceus) exposed to tributyltin (TBT) and benzo[a]pyrene (BaP). We constructed a cDNA library and cloned a 230-base sequence encoding partial CYP1A DNA. The CYP1A gene expression level was estimated using northern blotting. Hepatic CYP1A mRNA levels in fish injected with BaP at 10 mg/kg body weight (b.w.) increased for 48 h after injection. However, fish injected with both BaP and TBT at 10 mg/kg b.w. showed no significant changes in CYP1A mRNA level after 48 h. Plasma concentrations of testosterone and $17{\beta}$-estradiol were not significantly different in males and females injected with BaP and TBT. We suggest that TBT-induced suppression of BaP bioactivity should be interpreted with caution in biomonitoring field studies.

• Microbiology and Biotechnology Letters
• /
• v.19 no.5
• /
• pp.450-455
• /
• 1991

A protease hyperproducer, ampicillin resistant mutant, Serratia sp. SMNT-1 was selected from Serratia marcescens ATCC 21074 by mutagenesis. The protease productivity of this strain was about 11 times as much as that of the parental strain. The enzyme showed maximal activity at pH 9.0 and $40^{\circ}C$ and was stable over the pH range from 6.0 to 10.0 at $4^{\circ}C$, whereas it was unstable at $37^{\circ}C$ in alkaline condition. the enzyme was inactivated by heating at $60^{\circ}C$ for 10 min. The enzyme was inactivated by EDTA and reactivated by $Zn^{2+}, Co^{2+},\; and \; Mn^{2+}$, but the proteoiytic activity of the enzyme was not affected by DFP. From the above results, the protease produced by Serratia sp. SMNT-1 was classified as a metalloprotese.

• Resources Recycling
• /
• v.10 no.5
• /
• pp.16-21
• /
• 2001

Ultrafine $Mg(OH)l_2$and MgO powders were recovered from the waste solution containing $Mg^{++}$ which was a by-product of SHS (Self-propagating High temperature Synthesis)process. The optimum experimental conditions to prepare $Mg(OH)_2$were 13.0 of pH and 0.7M of $Mg^{++}$ content with addition of 9M of KOH as a pH regulator in acid leaching solution. Complete pre-cipitation of Mg(OH)$_2$from $Mg^{++}$ was realized at that condition. The dehydration reaction of the prepared Mg(OH)$_2$was studied by DSC, and the result was used for calcination process. In order to obtain MgO powder, dried Mg(OH)2 powder was calcined at $400~450^{\circ}C$. Particle size and shape of the prepared $Mg(OH)_2$and MgO powder was similar to those of the commercial powders.

• YAKHAK HOEJI
• /
• v.48 no.1
• /
• pp.1-5
• /
• 2004

The purpose of this study was to investigate the effect of coadministration and 3 days-pretreatmemt of niledipine (2, 10 mg/kg) on the pharmacokinetic parameters and bioavailability of paclitaxel (50 mg/kg) after oral administration in rats. Coadministration of nifedipine with paclitaxel did alter the $C_{max}$ (115${\pm}$29 ng/ml without nifedipine; 135${\pm}$35 ng/ml with nifedipine (10 mg/kg): p<0.05) and AUC (188${\pm}$459 ng/mlㆍhr with-out nifedipine; 2546${\pm}$642 ng/mlㆍhr with nifedipine; p<0.05). Three days treatment of nifedipine on the prior to paclitaxel administration increased the $t_{1/2}$ 〔9.90${\pm}$2.47 hr without nifedipine; 12.37${\pm}$3.12 hr with nifedipine (2 mg/kg): 12.83${\pm}$3.32 hr with nifedipine (10 mg/ml); p<0.05] and AUC [1833${\pm}$459 ng/mlㆍhr without nifedipine; 2663${\pm}$648 ng/mlㆍhr with nifedipine (2 mg/kg): 3006${\pm}$734 ng/mlㆍhr with nifedipine (10 mg/ml): p <0.05]. Drug interaction between nifedipine and paclitaxel decreased the elimination rate constant and increased the oral bioavailability of paclitaxel. On the basis of the results of this study, it might be considered that nifedip ine may inhibit cytochrome P450, which are engaged in paclitaxel metabolism, result in increased $t_{1/2}$ and AUC of paclitaxel. However, further study should be conducted to clarify the roles of cytochrome P450 and P-glycoprotein on paclitaxel bio-availability wit/or without nifedipine.

• Biomolecules & Therapeutics
• /
• v.18 no.3
• /
• pp.343-349
• /
• 2010

This study was designed to investigate the effects of ticlopidine on the pharmacokinetics of carvedilol after oral or intravenous administration of carvedilol in rats. Carvedilol was administered orally (3 mg/kg) or intravenously (1 mg/kg) without or with oral administration of ticlopidine (4, 12 mg/kg) to rats. The effects of ticlopidine on P-glycoprotein (P-gp) and cytochrome P450 (CYP) 2C9 activity were also evaluated. Ticlopidine inhibited CYP2C9 activity in a concentration-dependent manner with 50% inhibition concentration ($IC_{50}$) of $25.2\;{\mu}M$. In addition, ticlopidine could not significantly enhance the cellular accumulation of rhodamine 123 in MCF-7/ADR cells overexpressing P-gp. Compared with the control group (given carvedilol alone), the area under the plasma concentration-time curve (AUC) was significantly (12 mg/kg, p<0.05) increased by 14-41%, and the peak concentration ($C_{max}$) was significantly (12 mg/kg, p<0.05) increased by 10.7-73.3% in the presence of ticlopidine after oral administration of carvedilol. Consequently, the relative bioavailability (R.B.) of carvedilol was increased by 1.14- to 1.41-fold and the absolute bioavailability (A.B.) of carvedilol in the presence of ticlopidine was increased by 36.2-38.5%. Compared to the i.v. control, ticlopidine could not significantly change the pharmacokinetic parameters of i.v. administered carvedilol. The enhanced oral bioavailability of carvedilol may result from inhibition of CYP2C9-mediated metabolism rather than P-gpmediated efflux of carvedilol in the intestinal and/or in liver and renal eliminatin of carvedilol by ticlopidine.

• KOREAN JOURNAL OF CROP SCIENCE
• /
• v.12
• /
• pp.71-75
• /
• 1972

To investigate the effects of C. E. P. A(2-chloroethyl phosphonic acid) on the ripening of tobacco leaf, the effects on the yield and quality of leaf tobacco, this experiments were carried out during the period of from 1970 to 1971 at tobacco experiment station, Sosa, Korea and 3 locations. The results are summarized as follows. 1. The higher the C. E. P. A concentration was, the more the leaf ripening was accelerated. During the period from 3 to 4 days after treatment, the differences of leaf ripening among levels were prominent. 2. Treatment with C. E. P. A only on the upper surface of the tobacco leaf, accelerated the ripening of that particular part treated, but not apparently the other parts of leaf. 3. Distinctive acceleration of leaf ripening was, obserbed in the fully develope1lower leans, however, the upper leaves were indistinctive. 4. The higher C. E. P. A concentration was, the more the effect of ripening acceleration was. But the yield was reduced over 900ppm because of the low of growth of leaves and the reduced yield was 90% at the 3, 000ppm. So the proper concentration was regarded as 900ppm. 5. In the view point of the days of C. E. P. A ripening acceleration, it was shortened one days at 100 ppm, three days at 300ppm, three days at 450ppm, four days at 900ppm, seven days at 3, 000ppm. 6. In the point of curing process, it was possible that the curing time and fuel was reduced 29% and 45% respectively in the C. E. P. A treatment than the check. 7. Therefore, if it is treated the C. E. P. A at 900ppm in the tobacco cultivation, the quality shall be increased 13.5% and the price shall be increased 12% in the 10 Are. In the point of subsidiary affect, it is possible that the C. E. P. A ripening acceleration is shortened about 7 days at 3, 00ppm and curing time is shortened about 24 hours.

• The Journal of Korean Medicine
• /
• v.38 no.2
• /
• pp.15-30
• /
• 2017

Objectives: Hwangryunhaedok-tang (HHT; Huanglianjiedu-tang, Orengedoku-to), a traditional herbal formula, is used for treating inflammation, hypertension, gastritis, liver dysfunction, cerebrovascular diseases, dermatitis and dementia. The objective of this study was to assess the sub-acute toxicity of HHT in Sprague-Dawley (SD) rats, and its effect on the activities of human microsomal cytochrome P450s (CYP450s) and UDP-glucuronosyltransferases (UGTs). Methods: Male and female SD rats were orally administered HHT once daily at doses of 0, 500, 1000 and 2000 mg/kg for 4 weeks. We analyzed mortality, clinical observations, body weight, food consumption, organ weights, urinalysis, hematology, serum biochemistry, and histopathology. The activities of major human CYP450s (CYP1A2, CYP3A4, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP2E1) and UGTs (UGT1A1, UGT1A4, and UGT2B7) were assessed using in vitro fluorescence- and luminescence-based enzyme assays, respectively. Results: No toxicologically significant changes related to the repeated administration of HHT were observed in both male and female SD rats. The no observed adverse effect level (NOAEL) value was more than 2000 mg/kg/day for both sexes. HHT inhibited the activities of human microsomal CYP1A2, CYP2C19, CYP2D6, and CYP2E1, whereas it weakly inhibited the activities of CYP2B6, CYP2C9, CYP3A4, and UGT1A1. In addition, HHT negligibly inhibited the activities of human microsomal UGT1A4 and UGT2B7 with $IC_{50}$ values in excess of $1000{\mu}g/mL$. Conclusions: Our findings indicate that HHT may be safe for repeated administration up to 4 weeks. In addition, these findings provide information on the safety and effectiveness of HHT when co-administered with conventional drugs.

• Journal of Microbiology and Biotechnology
• /
• v.25 no.9
• /
• pp.1417-1424
• /
• 2015

In this study, we tried to characterize Streptomyces peucetius CYP157C4 with homology modeling using three cytochrome P450 (CYP) structures (CYP157C1, CYP164A2, and CYP107L1), having discovered that CYP157C4 lacks the ExxR motif that was considered invariant in all CYPs. We used Discovery Studio 3.5 to build our model after first assessing the stereochemical quality and side-chain environment, and a 7-ethoxycoumarin substrate was docked into the final model. The model-substrate complex allowed us to identify functionally important residues and validate the active-site architecture. We found a distance of 4.56 Å between the 7-ethoxycoumarin and the active site of the heme, and cloning and an in vitro assay of the CYP157C4 showed the dealkylation of the substrate. Since the details regarding this group of CYP structures are still unknown, the findings of this study may provide elucidation to assist with future efforts to find a legitimate substrate.

• Journal of Pharmaceutical Investigation
• /
• v.41 no.3
• /
• pp.153-159
• /
• 2011

This study was designed to investigate the effects of silibinin on the pharmacokinetics of carvedilol after oral administration of carvedilol in rats. Carvedilol was administered orally (3 mg/kg) with oral silibinin (0.3, 1.5 or 6 mg/kg) and intravenously (1 mg/kg) to rats. The effects of silibinin on P-glycoprotein (P-gp) and cytochrome P450 (CYP) 2C9 and CYP2D6 activity were also evaluated. Silibinin inhibited CYP2C9 and CYP2D6 enzyme activity with 50% inhibition concentration ($IC_{50}$) of 5.2 ${\mu}M$ and 85.4 ${\mu}M$, respectively. In addition, silibinin significantly enhanced the cellular accumulation of rhodamine-123 in MCF-7/ADR cells overexpressing P-gp. Compared with the control group, the area under the plasma concentration-time curve was significantly increased by 36.3-57.1%, and the peak concentration was significantly increased by 51.1-88.5% in the presence of silibinin after oral administration of carvedilol. Consequently, the relative bio-availability of carvedilol was increased by 1.13- to 1.57-fold and the absolute bioavailability was significantly increased by 38.6-59.7%. The time to reach peak concentration and the terminal half-life were not significant. The enhanced oral bio-availability of carvedilol may result from inhibition of CYP2C9-mediated metabolism and P-gp-mediated efflux of carvedilol rather than inhibition of CYP2D6-mediated metabolism in the intestine and/or in the liver by silibinin.

• Journal of the Korean Chemical Society
• /
• v.20 no.5
• /
• pp.431-437
• /
• 1976

On the condition of adequate air supply, complete removal of carbon monoxide,occurred above $650^{\circ}C$. Using catalysts, the oxidation of carbon monoxide occurred at lower temperatures; on both $MnO_2 \;and\;30%\;MnO_2-70%\;CuO\;at\;250{\circ}C,\;on\;CuO\;at\;450{\circ}C,\;on\;50%\;MnO_2-50%\;CuO\;at\;200{\circ}C,\;and\;on\;70%\;MnO_2-30%\;CuO\;at\;180{\circ}C$. Manganese dioxide (p-type) showed higher activity than cupric oxide (n-type) and a catalyst consisting of 60% $MnO_2-40%$ CuO had the highest activity of all the $MnO_2$-CuO mixture. Over the range of transitional temperature, carbon monoxide removal efficiency decreased linearly with increasing inlet carbon monoxide concentration while temperature was fixed. Residence time of gases in the catalytic reactor, in the range of 0.9 to 1.8 seconds, gave no effect on carbon monoxide conversion.